Type 2 Diabetes

Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.

The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

How can adolescent body mass index influence T2DM risk later in adulthood? A new study offers insight. 

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

Highlights include: "Artificial pancreas" improves glucose control; T1DM often misdiagnosed as T2DM; and a genetic connection for “type 1.5 diabetes.” 

New data suggest hepatitis C infection, but not hepatitis B infection, increases the prevalence of diabetes in patients who undergo kidney transplants.

Three new studies in diabetes research highlight the importance of whole grains and gluten in T2DM and T1DM risk.